https://orcid.org/0000-0002-5995-8542
References
- Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–1885. doi:https://doi.org/10.1056/NEJMra0902908.
- Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873–881. doi:https://doi.org/10.1182/blood-2014-03-563221.
- Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev. 2011;25(1):17–31. doi:https://doi.org/10.1016/j.blre.2010.09.003.
- Lyons RM, Marek BJ, Paley C, et al. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2014;38:149–154. doi:https://doi.org/10.1016/j.leukres.2013.11.004.
- Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38:557–563. doi:https://doi.org/10.1016/j.leukres.2014.02.003.
- Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicen-ter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res. 2010;34(7):864–870. doi:https://doi.org/10.1016/j.leukres.2009.12.004.
- Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol. 2010;28:2847–2852. doi:https://doi.org/10.1200/JCO.2009.25.2395.
- Lyons RM, Marek BJ, Paley C, et al. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2014;38:149–154. doi:https://doi.org/10.1016/j.leukres.2013.11.004.
- Waszczuk-Gajda A, Mądry K, Machowicz R, et al. Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first Polish MDS-PALG registry. Adv Clin Exp Med. 2016;25(4):633–641. doi:https://doi.org/10.17219/acem/62397.
- Xue Z, Xue Y, Zhi Z. A Chinese expert panel consensus statement on diagnosis and treatment of iron overload. Chin J Hematol. 2011;32(8):572–574.
- Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1–10. doi:https://doi.org/10.1007/s00277-010-1091-1.
- Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83–97. doi:https://doi.org/10.1111/bjh.14825.
- P1 B, Klersy C, Boni M, et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol. 2007;137(3):193–205.
- Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–4395.
- Barouk-Simonet E, Soenen-Cornu V, Roumier C, et al. Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. Cancer Genet Cytogenet. 2005;157(2):118–126.
- Campbell LI, Garson OM. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disoIdem. Leukemia. 1994;8(1):67–71.
- Tasaka T, Tohyama K, Kishimoto M, et al. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia. 2008;22(10):1874–1881. doi:https://doi.org/10.1038/leu.2008.199.
- Mies A, Platzbecker U. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors. Semin Hematol. 2017;54(3):141–146. doi:https://doi.org/10.1053/j.seminhematol.2017.06.004.
- Angelucci E, Cianciulli P, Finelli C, et al. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leuk Res. 2017;62:108–115. doi:https://doi.org/10.1016/j.leukres.2017.10.001.
- Messa E, Biale L, Castiglione A, et al. Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. Leuk Lymphoma. 2017;58(11):2752–2754. doi:https://doi.org/10.1080/10428194.2017.1312385.
- Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol. 2016;172(4):512–523. doi:https://doi.org/10.1111/bjh.13820.
- Shaw J, Chakraborty A, Nag A, et al. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. Eur J Haematol. 2017;99(5):399–408. doi:https://doi.org/10.1111/ejh.12936.
- Kim IH, Moon JH, Lim SN, et al. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Transfusion. 2015;55(7):1613–1620. doi:https://doi.org/10.1111/trf.13036.